Cypherpunk Technologies Inc (CYPH)
NASDAQFinancialsAsset ManagementSnapshot 2026-11-05
$2.47-13.94%
Close 2026-11-05 · 1-day change
NASDAQFinancialsAsset ManagementSnapshot 2026-11-05
QuarterlyIQ Insights · CYPH
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -27.2% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has erratic recent earnings surprises and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 26 industry peers
CYPH — earnings in line
Dated 2026-08-12
Results of Operations and Financial Condition On August 12, 2026, Cypherpunk Technologies Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026. The full text of the press release issued by the Company in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Company, whether made before or…
Why it matters: Cash use fell to $2.7 million in Q2, while cash was $7.6 million at quarter end. A rise could add pressure to fund operations.
Worry ifQ3 cash used for operations tops $2.7 million, or cash falls below the Q2 balance of $7.6 million.
Less concerning ifQ3 cash used for operations is $2.7 million or less, and cash stays at $7.6 million or more.
Why it matters: FDA alignment sets out a 270-patient trial plan. Enrollment would show that the program has moved from planning into testing.
Supportive ifLeap reports that its randomized Phase 3 trial has opened and is enrolling DKK1-high patients.
Worry ifLeap reports that the trial has not opened, enrollment is delayed, or a design change blocks the planned study.
Why it matters: ZEC price changes can swing reported earnings. Q2 net income included a $46.0 million unrealized gain.
Watch forQ3 results show a higher ZEC price than the prior quarter and a larger ZEC treasury, with an unrealized gain.
Also watch forQ3 results show a lower ZEC price than the prior quarter and an unrealized loss on ZEC holdings.
Why it matters: The FDA aligned with key parts of the trial plan, but Leap needs resources to start Phase 3. A deal could let the program move ahead.
Supportive ifA filing or company release names a partner, financing, or deal to fund the planned Phase 3 trial.
Worry ifThe company reports no deal or financing and says the planned Phase 3 trial cannot move forward.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$616 on $10,000 · ±6.2% | How much price usually moves either way. |
| Bad day | $1,577 loss on $10,000 · 15.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,271 loss on $10,000 · 82.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The new mining fleet added 3,023.13 ZEC in its first two weeks. Later output will show whether it keeps adding ZEC at that pace.
Watch forA company update says at least 3,023 ZEC were mined in a later two-week period. The mined ZEC went into the treasury.
Also watch forA company update says less than 3,023 ZEC were mined in a later two-week period, or that mining output fell.